Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -25.06
- Piotroski Score 2.00
- Grade Hold
- Symbol (BIOC)
- Company Biocept, Inc.
- Price $0.43
- Changes Percentage (-13.88%)
- Change -$0.07
- Day Low $0.40
- Day High $0.49
- Year High $27.00
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 05/08/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$48.17
- Trailing P/E Ratio -0.01
- Forward P/E Ratio -0.01
- P/E Growth -0.01
- Net Income $-32,087,000
Income Statement
Quarterly
Annual
Latest News of BIOC
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Banks are reporting a ten-fold surge in digital scams, cybersecurity firm BioCatch says
BioCatch, a cybersecurity firm from Tel Aviv, reported a tenfold surge in digital scams for U.S. and Canadian banks. Criminals are increasingly using social engineering tactics to dupe customers into ...
By CNBC | 5 days ago -
BioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highlights: Strong ORLADEYO Growth ...
Helen Thackray aims to demonstrate the effectiveness of Netherton syndrome treatment by focusing on skin penetration, target binding, and functional cure potential. Charlie Gayer expects continued ORL...
By Yahoo! Finance | 1 week ago -
BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript
BioCryst Pharmaceuticals provided insights in their Q3 2024 earnings call. The company emphasized continued growth in Orladeyo revenue and confidence in reaching sustainable profitability. They discus...
By Yahoo! Finance | 2 weeks ago
